Description
A sensitive biomarker for detecting and monitoring neurodegeneration
The Neurofilament Light Chain (NfL) test measures the concentration of a specific protein released into the blood or cerebrospinal fluid when nerve cells are damaged. Elevated NfL levels serve as an early and reliable marker of neurodegenerative processes in the brain and spinal cord.
Why the NfL Test Is Important
NfL has emerged as a powerful, non-invasive biomarker for detecting ongoing damage to neurons, even before structural changes appear on imaging. This test is increasingly used to aid in the diagnosis, prognosis, and monitoring of neurological diseases—especially those that progress over time.
Conditions Associated with Elevated NfL:
- Multiple Sclerosis (MS) – to monitor disease activity and response to therapy
- Amyotrophic Lateral Sclerosis (ALS) – to assess disease progression
- Alzheimer’s Disease & Other Dementias – as a biomarker for early neurodegeneration
- Parkinson’s Disease
- Traumatic Brain Injury (TBI)
- Stroke
- Peripheral Neuropathies or Inflammatory CNS Disorders
How This Test Helps:
- Detects early signs of neuronal injury
- Assesses disease severity and progression over time
- Helps monitor response to treatment in clinical and research settings
- Supports diagnosis when combined with imaging or other neurological evaluations
Who Should Consider This Test?
This test may be appropriate for individuals who:
- Are being evaluated for MS, ALS, or Alzheimer’s disease
- Have experienced neurological symptoms such as cognitive decline, tremors, weakness, or memory loss
- Have a family history of neurodegenerative disorders
- Are participating in a clinical trial or being treated with neuroprotective therapies
- Want to track the effectiveness of disease-modifying treatments
Specimen Type: Blood Draw
Fasting: Not required
